BCMA (CD269/TNFRSF17)-BINDENDE PROTEINE
European patent · EP3415531 · In force
Register entry
- Publication number
- EP3415531
- Application number
- EP18163942
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- May 24, 2012
- Published
- Dec 19, 2018
- Granted
- Sep 6, 2023
- Protection ends at the latest
- May 23, 2032
- Next annual fee due
- May 31, 2027
- IPC classes
- C07K 16/28 (2006.01)A61K 39/00 (2006.01)A61K 47/68 (2017.01)
- Priority
- US 201161490732 P 27.05.2011US 201261647196 P 15.05.2012
- Filing language
- English
- Source
- Swissreg
Supplementary protection certificates
A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Jun 1, 2026
Change
Published in Swissreg on 01.06.2026
- Dec 23, 2025
Holder’s address changed
- Owner
- Glaxo Group Limited, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom → Glaxo Group Limited, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom
Published in Swissreg on 23.12.2025
- Jun 1, 2025
Change
Published in Swissreg on 01.06.2025
- Jul 17, 2024
Change
Published in Swissreg on 17.07.2024
- Jun 2, 2024
Change
Published in Swissreg on 02.06.2024
- Sep 6, 2023
Granted
Published in Swissreg on 06.09.2023
Parties
Inventor
Stevenage, Hertfordshire SG1 2NY, GB
Stevenage, Hertfordshire SG1 2NY, GB
Stevenage, Hertfordshire SG1 2NY, GB
Issaquah, WA, US
Collegeville, PA 19426-0989, US
Stevenage, Hertfordshire SG1 2NY, GB
Stevenage, Hertfordshire SG1 2NY, GB
Stevenage, Hertfordshire SG1 2NY, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.